Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Siebenhofer, A; Ulrich, LR; Mergenthal, K; Roehl, I; Rauck, S; Berghold, A; Harder, S; Gerlach, FM; Petersen, JJ.
Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial.
Implement Sci. 2012; 7(10):79-79 Doi: 10.1186/1748-5908-7-79 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Siebenhofer-Kroitzsch Andrea
Co-Autor*innen der Med Uni Graz
Berghold Andrea
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Background: Antithrombotic treatment is a continuous therapy that is often performed in general practice and requires careful safety management. The aim of this study is to investigate whether a best-practice model that applies major elements of case management and patient education, can improve antithrombotic management in primary healthcare in terms of reducing major thromboembolic and bleeding events. Methods: This 24-month cluster-randomized trial will be performed with 690 adult patients from 46 practices. The trial intervention will be a complex intervention involving general practitioners, healthcare assistants, and patients with an indication for oral anticoagulation. To assess adherence to medication and symptoms in patients, as well as to detect complications early, healthcare assistants will be trained in case management and will use the Coagulation-Monitoring List (Co-MoL) to regularly monitor patients. Patients will receive information (leaflets and a video), treatment monitoring via the Co-MoL and be motivated to perform self-management. Patients in the control group will continue to receive treatment as usual from their general practitioners. The primary endpoint is the combined endpoint of all thromboembolic events requiring hospitalization and all major bleeding complications. Secondary endpoints are mortality, hospitalization, strokes, major bleeding and thromboembolic complications, severe treatment interactions, the number of adverse events, quality of anticoagulation, health-related quality of life, and costs. Further secondary objectives will be investigated to explain the mechanism by which the intervention is effective: patients' assessment of chronic illness care, self-reported adherence to medication, general practitioners' and healthcare assistants' knowledge, and patients' knowledge and satisfaction with shared decision making. Practice recruitment is expected to take place between July and December 2012. Recruitment of eligible patients will start in July 2012. Assessment will occur at three time points: baseline and follow-up after 12 months and after 24 months. Discussion: The efficacy and effectiveness of individual elements of the intervention, such as antithrombotic interventions, self-management concepts in orally anticoagulated patients, and the methodological tool of case management, have already been extensively demonstrated. This project foresees the combination of several proven instruments, as a result of which we expect to profit from a reduction in the major complications associated with antithrombotic treatment.
Find related publications in this database (using NLM MeSH Indexing)
Administration, Oral -
Case Management - organization & administration
Clinical Protocols -
Fibrinolytic Agents - administration & dosage
Health Personnel - organization & administration
Humans -
Medication Adherence -
Multicenter Studies as Topic -
Patient Education as Topic -
Patients -
Primary Health Care - organization & administration
Randomized Controlled Trials as Topic -
Research Design -

Find related publications in this database (Keywords)
Oral anticoagulation
Best-practice model
Case management
© Med Uni Graz Impressum